References
- Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.
- Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107–115.
- Geddawy A, Ibrahim YF, Elbahie NM, et al. Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. J Transl Int Med. 2017;5:8–17.
- Chan J, Chung R. Perspectives on HCV: current therapeutic regimens and drug–drug interactions. Clin Pharmacol Drug Dev. 2017;6:147–163.
- Zepatier® SmPC. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004126/WC500211235.pdf
- Exviera® SmPC. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf
- Viekirax® SmPC. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf
- Epclusa® SmPC. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/004210/WC500211151.pdf
- Daklinza® SMPC. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf
- Harvoni® SMPC. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf
- Olysio® SMPC. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002777/WC500167867.pdf
- Vosevi® SMPC. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004350/WC500235373.pdf
- Maviret® SMPC. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004430/WC500233677.pdf
- Talavera Pons S, Boyer A, Lamblin G, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol. 2017;83:269–293.
- Kondili LA, Gaeta GB, Ieluzzi D, et al. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study. PLoS One. 2017;12(2):e0172159X.
- Kiser JJ, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.
- Kunze A, Huwyler J, Camenisch G, et al. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol. 2012;84:1096–1102.
- van Heeswijk RP, Beumont M, Kauffman RS, et al. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther. 2013;18:553–560.
- Hulskotte EGJ, Gupta S, Xuan F, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. Global Antiviral J. 2011;7(1): 108–109. Abstract.
- Rpg VH, Boogaerts G, De Paepe E, et al. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. Rev Antiviral Ther Infect Dis. 2010;5:12–13.
- Kasserra C, Hughes E, Treitel M, et al.: Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, USA; 2011.
- Garg V, Chandorkar G, Farmer HF, et al. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol. 2012;52(10):1566–1573.
- Luo X, Rpg VH, Alves K, et al. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract PK_11]. Rev Antiviral Ther Infect Dis. 2011;6:13.
- Luo X, Trevejo J, van Heeswijk RP, et al. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother. 2012;56(7):3641–3647.
- Hulskotte EGJ, Hwa-Ping F, Bruce RD, et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy [abstract PK_09]. Cambridge, MA: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 2012. Rev Antiviral Ther Infect Dis. 2012;6:12.
- Sockalingam S, Tseng S, Giguere P, et al. Psychiatric treatment considerations with direct-acting antivirals in hepatitis C. BMC Gastroenterol. 2013;13:86.
- Burger D, Back D, Buggisch P, et al. Clinical management of drug–drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58:792–800.
- Smolders EJ, de Kanter CT, de Knegt RJ, et al. Drug-drug interactions between direct-acting antivirals and psychoactive medications. Clin Pharmacokinet. 2016;55:1471–1494.
- King JR, Menon RM. Ombitasvir/paritaprevir/ritonavir and dasabuvir: drug interactions with antiretroviral agents and drugs forsubstance abuse. Clin Pharmacol Drug Dev. 2017;6(2):201–205.
- Langness J, Nguyen M, Wieland A, et al. Optimizing hepatitis C virus treatment through pharmacist interventions: identification and management of drug-drug interactions. World J Gastroenterol. 2017;23:1618–1626.
- Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opin Drug Metab Toxicol. 2016;12:721–731.
- Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, et al. Drug–drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet. 2016;55:197–208.
- Scavone C, Sportiello L, Rafaniello C, et al. New era in treatment options of chronic hepatitis C: focus on safety of newdirect-acting antivirals (DAAs). Expert Opin Drug Saf. 2016;15(sup2):85–100.
- Smolders EJ, Smit C, de Kanter C, et al. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect. HIV Med. 2018;19(3):216–226.
- Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir. Antimicrob Agents Chemother. 2015;60:105–114.
- Roncero C, Fuster D, Palma-Álvarez RF, et al. HIV and HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study. Aids Care. 2017;29:1551–1556.
- Roncero C, Vega P, Martinez-Raga J, et al. Chronic hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment. Adicciones. 2017;29(2):71–73.
- Bracchi M, Stuart D, Castles R, et al. Increasing use of ‘party drugs’ in people living with HIV on antiretrovirals: a concern for patient safety. Aids. 2015;29:1585–1592.
- McCall H, Adams N, Mason D, et al. What is chemsex and why does it matter? BMJ. 2015;351:5790.
- Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57(6):1379–1390.
- Alvarez FJ. Fundamentos Farmacológicos. In: Roncero C, Casas M, Patología Dual. Fundamentos clínicos y terapéuticos, Marge Books. Barcelona; 2016. p. 43–55. ISBN 978-84-15004-54-7 DL-B 7448-2016.
- El–Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476–482.
- Stewart B, Mikocka-Walus A, Morgan J, et al. Anxiety and depression in Australian chronic hepatitis C outpatients: prevalence and predictors. Australas Psychiatry. 2012;20:496–500.
- Muga R, Zuluaga P, Sanvisens A, et al. Hepatitis C associated to substance abuse: ever closer to a treatment without interferon. Adicciones. 2015;27:141–149.
- Roncero C, Littlewood R, Vega P, et al. Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment. Eur J Gastroenterol Hepatol. 2017;29(6):629–633.
- Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–583.
- Gervasoni C, Peri AM, Cattaneo D, et al. Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy. Eur J Clin Pharmacol. 2015;71:1027–1028.
- Garimella T, Wang R, Luo WL, et al. Assessment of drug- drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob Agents Chemother. 2015;59:5503–5510.
- Lazarus JV, Sperle I, Maticic M, et al. A systematic review of hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infect Dis. 2014;14:S16.
- WHO Regional Office for Europe. Good governance for prison health in the 21st century. Copenhagen: UNODC; 2013.
- Marco A, Antón JJ, Saiz de la Hoya P, et al. PERSEO group. Personality disorders among Spanish prisoners starting hepatitis C treatment: prevalence and associated factors. Psychiatry Res. 2015;230:749–756.
- WHO. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. 2016 June. [cited 2017 Mayz 21]. Available from: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
- Marshall A, Cunningham E, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125–133.
- Wright N, Reimer J, Somaini L, et al. Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model. J Gastroenterol Hepatol. 2017;29(11):1206–1214.
- Evren C, Bilici R, Ucbilek E, et al. A call for action for hepatitis C infection among people who inject drugs in Turkey. Dusunen Adam J Psychiatry Neurol Sci. 2017;30:271–277.